Research Paper Volume 12, Issue 20 pp 20254—20267
Development and validation of an immune and stromal prognostic signature in uveal melanoma to guide clinical therapy
Figure 7. Subgroup analysis and risk score distribution. (A) Box-plot analysis of high and low groups in CTLA-4 and PD-L1 expression. (B) The association between risk score distribution and established prognostic markers, including BAP1 mutant, tumor stage, histological type, chromosome 3 status, and molecular subtype. (C) The 3 years area under the curve (AUC) of risk score and prognostic markers (BAP1 mutant, tumor stage, histological type, chromosome 3 status and molecular subtype) associated with OS in TCGA. *P < 0.05, ** P < 0.01,***P < 0.001,****P < 0.0001.